PCC framework of this scoping review
| Population | Preterm infants born at <34 weeks of gestation and treated with iNO after 7 days of age |
| Concept | Aim to identify the initiation criteria of iNO, postnatal day of the iNO initiation, dosage of iNO (ppm), duration of iNO therapy, discontinuation criteria of iNO therapy, concomitant use of other drugs and adverse effects |
| Context | Published between January 2003 and August 2023 Conducted in developed countries Published in English or Japanese Randomised controlled trial, cohort study, case–control study and case series Excluding congenital malformation syndrome and a chromosomal abnormality |
iNO, inhaled nitric oxide; PCC, Population-Concept-Context; ppm, parts per million.